Domestic Cervical Cancer Vaccine starts today at 329 yuan/injection, and appointments are available in many places

Economic Observation Network reporter Qu Yixian domestic cervical cancer vaccine began vaccination today (May 18), and the first injection was given at Hubei Maternity and Child Health Hospital in Wuhan. The vaccinator was a 10-year-old girl. The girl's mother, Ms. Peng, is an obstetrician at the Hubei Provincial Maternal and Child Health Hospital. She is the second vaccinator. The

Economic Observation Network has learned that the domestic cervical cancer vaccine is priced at 329 yuan per shot. In addition to Hubei, Xinjiang, Jiangxi, Yunnan and other regions can also make appointments for vaccination. The

cervical cancer vaccine (HPV vaccine for short) is mainly used to prevent cervical cancer in women. According to the types of virus subtypes covered by the vaccine, cervical cancer vaccines can be divided into two-valent, four-valent and nine-valent. The bivalent HPV vaccine has a protective effect on two high-risk types (HPV-16 and HPV-18), and 84.5% of cervical cancers in the Chinese population are caused by these two. Four-valence adds two low-risk types HPV-6 and HPV-11 on the basis of two-valence, which can reduce the occurrence of genital warts, while nine-valence adds five high-risk types to four-valence.

Yi Nianhua, director of the Women's Health Department of Hubei Maternal and Child Health Hospital, said that cervical cancer is the only cancer that can be prevented by vaccination. Vaccination and regular screening are necessary measures to prevent cervical cancer.

In the domestic vaccination market, the bivalent HPV Cecolin (Cecolin) produced by Xiamen Wantai Canghai Biotechnology Co., Ltd. is suitable for women aged 9-45, 2 injections for 9-14 years old, and 3 injections for 15-45 years old; GlaxoSmithKline's (GSK) divalent HPV is suitable for women aged 9-45, with 3 doses; Merck’s quadrivalent HPV and 9-valent HPV are suitable for women aged 20-45 and 16-26, with 3 doses .

Nine-valent seedlings are most sought after by adult women. But in fact, the protection rate of bivalent vaccine and nine-valent vaccine is not much different, the protection rate of bivalent HPV is 84.5%, and the protection rate of nine-valent HPV is 90%. The World Health Organization (WHO) pointed out in 2017: “Existing evidence shows that from a public health perspective, bivalent, quadrivalent and ninth-valent vaccines have no immunogenicity, efficacy and effectiveness in preventing HPV-related types 16 and 18 from cervical cancer. The three vaccines can prevent most related cancers.” Professor Sui Long from the Obstetrics and Gynecology Hospital of Fudan University also said that many people have misunderstandings about HPV vaccines, thinking that the higher the price, the higher the cancer prevention coefficient. . But in fact, the four HPV vaccines currently approved for marketing in China have no difference in terms of immunogenicity, efficacy and effectiveness in preventing HPV-related types 16 and 18, and can prevent most cervical cancers. Vaccination should be carried out as soon as possible before the arrival of the first peak infection age group (15-24 years old). The younger the age, the earlier protection will be obtained. A reporter from the

Economic Observation Network previously saw in a community hospital in Putuo District, Shanghai that the price of the nine-valent HPV vaccine was about 1,300 yuan per shot, the price of the quadrivalent HPV vaccine was about 800 yuan per shot, and the imported bivalent HPV vaccine was about 600 yuan. /Injection, the corresponding total vaccination costs are 3900 yuan, 2400 yuan and 1800 yuan respectively.

domestically produced Xinkening is priced at 329 yuan per injection, the cost of two injections for 9-14 years old is 658 yuan, and the cost of three injections for 15-45 years old is 987 yuan, which has a price advantage compared with imported HPV. According to public data from

, ​​since the first HPV vaccine was launched in 2006, the current cumulative sales of HPV vaccines are about 350 million, and the annual demand is 100 million, and the demand is increasing. According to data from the China Institute for Food and Drug Control, 1.46 million HPV vaccines were issued in China in 2017, 7 million in 2018, and 8.7 million in January-November 2019. Based on 356 million women of the right age and 3 needles per person, the market gap in China exceeds 1 billion.

It is worth noting that 9-14 years old is the best age group recommended by WHO for HPV vaccination. More than 104 countries and regions around the world have included HPV vaccine in their national immunization programs, and the main vaccinated population is 9-14 years old.